Item 5. Market for Registrant’s Common Equity
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Market Information.
Our common stock is qualified for quotation on the
OTCQX under the symbol “MDNC” and has been only recently quoted on the OTC since March 2023. There currently is no liquid
trading market for our common stock. There can be no assurance that a significant active trading market in our common stock will develop,
or if such a market develops, that it will be sustained.
The ability of individual stockholders to trade their
shares in a particular state may be subject to various rules and regulations of that state. A number of states require that an issuer’s
securities be registered in their state or appropriately exempted from registration before the securities are permitted to trade in that
state. Presently, we have no plans to register our securities in any particular state. Further, our shares may be subject to the provisions
of Section 15(g) and Rule 15g-9 of the Exchange Act, commonly referred to as the “penny stock” rule. Section 15(g) sets forth
certain requirements for transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in
Rule 3a51-1 of the Exchange Act.
Holders
As
of May 22, 2023, we had 63 shareholders of common stock per transfer agent’s shareholder list.
Dividends
The Company has not paid any cash dividends to date
and does not anticipate or contemplate paying any dividends in the foreseeable future. It is the present intention of management to utilize
all available funds for the growth of the Registrant’s business.
Equity Compensation Plan Information
The Company does not currently have an equity compensation
plan in place.
Recent Sales of Unregistered Securities
On April 26, 2021 the company issued 10,000,000 shares
of common stock to the founding shareholders at 0.001 per share.
On May 30, 2022, the company concluded a pre Trachealator
FDA approval raise which started in October 2021 and concluded on May 30, 2022. This raise was for a total of 1,733,750 shares of common
stock at $2 a share.
These securities were issued pursuant to Regulation
S promulgated under the Securities Act of 1933, as amended. The holders represented their intention to acquire the securities for investment
only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision.
We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the
appropriate restrictive legend affixed to the restricted stock.
ITEM 6.
[RESERVED]
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.